NS
$3.95
+0.03
(+0.77%)
As of Oct 5, 2026, 3:43 PM EDT
Price history
Nasus Pharma (NSRX) is trading up at $3.95 (+0.77%), as of the latest quote. It operates in the Health Care sector.
IPO: August 13, 2025 · $8.00 offering · NYSE · View IPO details →
Nasus Pharma revenue & net income history (FY2023–FY2025)
RevenueNet income
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | $1.24B |
| Operating income | −$1.15M | −$1.08M | −$4.90M |
| Operating margin | — | — | −0.4% |
| Net income | −$1.05M | −$1.53M | −$5.86M |
| Net margin | — | — | −0.5% |
| EPS (diluted) | −$0.20 | −$0.22 | −$0.72 |
| Balance sheet | |||
| Cash and equivalents | $193.0K | $284.0K | $1.24M |
| Total assets | — | $717.0K | $5.00M |
| Total liabilities | — | $3.93M | $2.24M |
| Shareholders' equity | −$3.80M | −$3.21M | $2.77M |
| Cash flow | |||
| Operating cash flow | −$1.03M | −$665.0K | −$4.92M |
| Capital expenditure | — | — | $14.0K |
| Free cash flow | — | — | −$4.93M |
From Nasus Pharma's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
About Nasus Pharma
- Headquarters
- Tel Aviv - Yafo, Israel From SEC filings, Oct 2026
Recent News (5)
-
Nasus Pharma stock reiterated at Market Outperform by Citizens
Nasus Pharma stock reiterated at Market Outperform by Citizens
-
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
-
-
Nasus Pharma Announces Transition of Chief Financial Officer TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the develop…
-
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of i…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International